Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SI | P14410 | 2/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23391871 | 0.83 | MGAM (0.39) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL19677667 | 0.83 | EGLN1 (0.38) | TSHRALDH1A1 | |
| SCHEMBL28746307 | 0.81 | ALDH1A1 (0.31) | TET2ALDH1A1 | |
| SCHEMBL2471546 | 0.79 | ALDH1A1 (0.39) | TET2TSHRALDH1A1 | |
| SCHEMBL15120652 | 0.79 | CES2 (0.39) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL26885023 | 0.78 | CES2 (0.42) | TSHRALDH1A1 | |
| SCHEMBL25635527 | 0.76 | CA2 (0.35) | ALDH1A1 | |
| SCHEMBL18560606 | 0.76 | MGAM (0.37) | MGAMGAASIMGAM2TET2 | |
| SCHEMBL17964096 | 0.76 | GAA (0.52) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL9036175 | 0.76 | GAA (0.50) | MGAMGAASIMGAM2TET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365667-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-07-22 | — | — | US | disclosed |
| WO-2025078335-A1 | PROCESSES FOR THE PREPARATION OF DEUCRAVACITINIB | FARMHISPANIA GROUP, S.L. (ES) | 2025-04-17 | — | — | WO | disclosed |
| EP-4538259-A1 | PROCESSES FOR THE PREPARATION OF DEUCRAVACITINIB | Farmhispania Group, S.L. (ES) | 2025-04-16 | — | — | EP | disclosed |
| US-20240002364-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | US | disclosed |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2021-08-19 | — | — | US | disclosed |
| US-11021462-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3713930-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | HOFFMAN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | HOFFMAN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| CN-1657523-A | Cyclic compounds | TANABE SEIYAKU CO (JP) | 2005-08-24 | — | — | CN | disclosed |
| US-20040142930-A1 | Cyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-22 | — | — | US | disclosed |
| US-20030229089-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-11 | — | — | US | disclosed |
| CN-1440393-A | cyclic compound | TANABE SEIYAKU CO (JP) | 2003-09-03 | — | — | CN | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021462-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | MGAM 3181/4885GAA 4444/4885SI 2916/4885 |
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | TYK2, JAK3, JAK2 | MGAM 3181/4885GAA 4444/4885SI 2916/4885 |
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | SYK, BTK, IRAK2 | MGAM 3343/4885GAA 2403/4885SI 4272/4885 |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | MGAM 3181/4885GAA 4444/4885SI 2916/4885 |
| US-20240002364-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | TYK2, JAK3, JAK2 | MGAM 3181/4885GAA 4444/4885SI 2916/4885 |
| US-20030229089-A1 | Cyclic compounds | PDE3B, PDE5A, PDE9A | MGAM 3625/4885GAA 698/4885SI 1650/4885 |
| US-12365667-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | MGAM 3181/4885GAA 4444/4885SI 2916/4885 |
| US-20040142930-A1 | Cyclic compounds | PDE3B, PDE4A, PDE5A | MGAM 3883/4885GAA 844/4885SI 2016/4885 |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | TYK2, JAK1, JAK3 | MGAM 4005/4885GAA 4020/4885SI 4737/4885 |
| US-20080027037-A1 | Cyclic compounds | PDE4A, PDE4B, PDE3B | MGAM 4228/4885GAA 1933/4885SI 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.